Salmonella Typhimurium expressing chromosomally integrated Schistosoma mansoni Cathepsin B protects against schistosomiasis in mice

Hassan, Adam S; Houle, Sébastien; Labrie, Lydia; Perera, Dilhan J; Dozois, Charles M. ORCID: https://orcid.org/0000-0003-4832-3936; Ward, Brian J. et Ndao, Momar (2023). Salmonella Typhimurium expressing chromosomally integrated Schistosoma mansoni Cathepsin B protects against schistosomiasis in mice NPJ Vaccines , vol. 8 , nº 1:27. pp. 1-13. DOI: 10.1038/s41541-023-00599-w.

Prévisualisation

PDF - Version publiée Disponible sous licence Creative Commons Attribution. Télécharger (1MB) | Prévisualisation

Résumé

Schistosomiasis threatens hundreds of millions of people worldwide. The larval stage of Schistosoma mansoni migrates through the lung and adult worms reside adjacent to the colonic mucosa. Several candidate vaccines are in preclinical development, but none is designed to elicit both systemic and mucosal responses. We have repurposed an attenuated Salmonella enterica Typhimurium strain (YS1646) to express Cathepsin B (CatB), a digestive enzyme important for the juvenile and adult stages of the S. mansoni life cycle. Previous studies have demonstrated the prophylactic and therapeutic efficacy of our plasmid-based vaccine. Here, we have generated chromosomally integrated (CI) YS1646 strains that express CatB to produce a viable candidate vaccine for eventual human use (stability, no antibiotic resistance). 6-8-week-old C57BL/6 mice were vaccinated in a multimodal oral (PO) and intramuscular (IM) regimen, and then sacrificed 3 weeks later. The PO + IM group had significantly higher anti-CatB IgG titers with greater avidity and mounted significant intestinal anti-CatB IgA responses compared to PBS control mice (all P < 0.0001). Multimodal vaccination generated balanced T(H)1/T(H)2 humoral and cellular immune responses. Production of IFNγ by both CD4(+) and CD8(+) T cells was confirmed by flow cytometry (P < 0.0001 and P < 0.01). Multimodal vaccination reduced worm burden by 80.4%, hepatic egg counts by 75.2%, and intestinal egg burden by 78.4% (all P < 0.0001). A stable and safe vaccine that has both prophylactic and therapeutic activity would be ideal for use in conjunction with praziquantel mass treatment campaigns.

Type de document:	Article
Mots-clés libres:	Live attenuated vaccines, Parasitic infection
Centre:	Centre INRS-Institut Armand Frappier
Date de dépôt:	19 juill. 2023 05:19
Dernière modification:	19 juill. 2023 05:19
URI:	https://espace.inrs.ca/id/eprint/13397

Gestion Actions (Identification requise)

Modifier la notice